CARM1-IN-4
CARM1-IN-4 (compound 11f) is a potent CARM1 inhibitor with IC50s of 9 nM and 56 nM for CARM1 and PRMT1, respectively. CARM1-IN-4 displays significant anti-proliferative effects on colorectal cancer cell lines. CARM1-IN-4 effectively inhibits the methyltransferase activity of CARM1 and prevents methylation of downstream proteins. CARM1-IN-4 induces apoptosis and shows antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 2878481-07-1
- Formula: C24H42N2O4
- Molecular Weight:422.60
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Histone Methyltransferase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CARM1 9 nM (IC50) |
PRMT1 56 nM (IC50) |
PRMT6 30 nM (IC50) |
PRMT8 31 nM (IC50) |
PRMT3 2637 nM (IC50) |
PRMT5 >100,000 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
3.13 μM
Compound: 11f
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth by CCK-8 assay
|
[PMID: 38460270] |
In Vitro
CARM1-IN-4 (compound 11f) exhibits significant anti-proliferative activity in the HCT116 cell lines (IC50=3.13 μM)[1].
CARM1-IN-4 (0.625-5 μM; 72 h) causes a dose-dependent induction of apoptosis in HCT116 cell[1].
CARM1-IN-4 (0.625-10 μM; 48 h) effectively inhibits the methyltransferase activity of CARM1, influencing the levels of asymmetric demethylation on CARM1 substrates within a cellular environment[1].
CARM1-IN-4 exhibits a relatively high mitochondrial stability, with an extended half-life in mouse mitochondria (T1/2=217 min)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cells
-
Concentration:0.625, 1.25, 2.5, 5 μM
-
Incubation Time:72 h
-
Result:Illustrated a noticeable increase in the overall percentages of both early and late apoptotic cells.
-
Cell Line:HCT116 cells
-
Concentration:0.625, 1.25, 2.5, 5, 10 μM
-
Incubation Time:48 h
-
Result:Caused dose-dependent reductions in global asymmetric dimethylarginine (aDMA) and asymmetric dimethyl-PABP1 levels in HCT116 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6 to 8-week-old female BALB/c nude mice bearing subcutaneous HCT116 xenograft[1]
-
Dosage:10, 25 mg/kg
-
Administration:Intraperitoneal injection; daily; for 12 days
-
Result:Showed evident inhibitory effect.
Chemical Information
-
CAS No. 2878481-07-1
-
Molecular Weight 422.60
-
Formula C24H42N2O4
-
SMILES
CN(C[C@@H](O)CNC)CC1=CC=CC=C1OC2CCC(COCC)(COCC)CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)